Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Good financial results growth rate 44.3% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-0.9%)
  • Dividend yield for the last twelve months 4.3%
  • Free cash flow yield 7.1% (LTM)
  • Share price is 45.3% higher than minimum and 22.7% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (19.3x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (+2.9%)57.62
year average price 50.18  


year start price 57.42 2025-02-06

max close price 63.11 2025-03-10

min close price 42.60 2025-10-29

current price 57.62 2026-02-05
Common stocks: 2 111 517 922

Dividend Yield:  4.3%
FCF Yield LTM: 7.1%
EV / LTM EBITDA: 19.3x
EV / EBITDA annualized: 12.4x
Last revenue growth (y/y):  +2.8%
Last growth of EBITDA (y/y):  +85.8%
Historical revenue growth:  +1.0%
Historical growth of EBITDA:  -2.8%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 121 666
Net Debt ($m): 33 300
EV (Enterprise Value): 154 966
EBITDA LTM ($m): 8 033
EV / LTM EBITDA: 19.3x
Price to Book: 6.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-03zacks.com

Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?

2026-02-02zacks.com

Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?

2026-01-30zacks.com

Will BMY's Oncology Collaborations Drive Its Next Growth Phase?

2026-01-24seekingalpha.com

Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)

2026-01-23fool.com

AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term.

2026-01-23seekingalpha.com

Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion

2026-01-22zacks.com

Is BMY's Deep Pipeline the Key to Its Next Growth Phase?

2026-01-22reuters.com

Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug

2026-01-22seekingalpha.com

Top 10 Dividend Stocks For Uncertain Times

2026-01-21youtube.com

Final Trade: BMY, IGV, SOXX, GEN, AMZN
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data